Summary
Alnylam Pharmaceuticals, Inc. (ALNY) announced a key leadership change within its finance department, effective July 1, 2016. David-Alexandre C. Gros, M.D., currently Senior Vice President and Chief Business Officer, will assume the role of Principal Financial Officer. Dr. Gros, who joined Alnylam in June 2015, brings extensive experience from previous roles at Sanofi SA and in investment banking and management consulting. This transition is part of a planned succession and does not involve any change in compensation for Dr. Gros or the outgoing Principal Financial Officer, Michael P. Mason. Michael P. Mason will continue as Vice President, Finance and Treasurer, and will also retain his role as Principal Accounting Officer, overseeing the company's finance operations. This filing provides assurance to investors that the company's financial leadership is being managed with continuity and that key personnel remain in place to support Alnylam's strategic objectives. Investors should note Dr. Gros's background in business development and strategy as he takes on broader financial responsibilities.
Key Highlights
- 1Effective July 1, 2016, Dr. David-Alexandre C. Gros appointed as Principal Financial Officer, succeeding Michael P. Mason.
- 2Dr. Gros currently serves as Senior Vice President and Chief Business Officer.
- 3Michael P. Mason will remain as Vice President, Finance and Treasurer, and will continue as Principal Accounting Officer.
- 4The leadership changes are part of a planned succession and do not involve any change in compensation for Dr. Gros or Mr. Mason.
- 5Dr. Gros's prior experience includes executive roles at Sanofi SA, investment banking, and management consulting.
- 6This filing focuses on changes in principal officers and does not contain new financial performance data or clinical trial updates.